Skip to main content

Statute

BPCIA

102 published works

  1. BioLoquitur

    Webinar: Biosimilar Litigation and Your BPCIA Compliance: Key Strategies In Light of AbbVie v. Boehringer

    By Dean L. Fanelli, Ph.D., Jamaica Szeliga

    This webinar is hosted by The Knowledge Group. On March 22nd at 12 p.m. ET, Dean Fanelli and Jamaica Szeliga, along with Timothy Shea of Sterne, Kessler, Goldstein & Fox…

  2. IP Intelligence

    Federal Circuit Suggests Solution to Patent Owner’s Dilemma When Applicant for Biosimilar Product Refuses Discovery

    By Allen Sokal

    In Amgen, Inc. v. Hospira, Inc., Appeal No. 2016-2179 (Fed. Cir. Aug. 10, 2017), the Federal Circuit suggested what an owner of a reference product suing an applicant for a…

  3. The IP Law Blog

    U.S. Supreme Court Allows Early Notice For Biosimilars

    By Eric Caligiuri

    In SANDOZ INC. v. AMGEN INC. et al., the United States Supreme Court in a unanimous opinion ruled that biosimilar makers can give their required 180-day statutory notice of sales…

  4. Biosimilars Law Blog

    Supreme Court Issues Landmark Biosimilar Ruling

    By Philip Katz, David Fox, Gary Veron, James Allred

    On June 12, 2017, the Supreme Court issued a unanimous ruling in Sandoz Inc. v. Amgen Inc. The case interprets two provisions of the Biologics Price Competition and Innovation Act…

  5. Biosimilars Law Bulletin

    Janssen Files BPCIA Patent Infringement Suit Against Samsung Bioepis’s Renflexis® (infliximab-abda)

    By Nicole Gifford

    Earlier this month, Janssen Biotech, Inc., a subsidiary of Johnson and Johnson,   (“Janssen” or “Plaintiff”) filed a Complaint in the United States District Court for the District of New Jersey…

  6. Biosimilars Law Bulletin

    Litigation Spotlight: The Infliximab (Remicade®) Litigation

    By Daniel R. McCallum

    Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and only two of those products are commercially…

  7. Biosimilars Law Bulletin

    Briefing Completed in Supreme Court’s First Biosimilar Case

    By Nicole M. DeAbrantes

    As we previously reported in this post, the Supreme Court granted certiorari in its first biosimilar case on Sandoz’s petition in Sandoz, Inc. v. Amgen, Inc., et al., Case No.…

  8. IP Intelligence

    A Split Decision Remains Split; No en banc Review of Amgen v. Sandoz

    By Ron Kern

    On October 16, 2015, the Court of Appeals for the Federal Circuit (“Federal Circuit”) opted not to rehear its previously issued split decision in the court’s first analysis of the…

  9. Biosimilars Law Blog

    FDA Updates U.S. Biosimilar Guidances

    By Marie A. Vodicka

    Five years after enactment of the BPCIA and following its first biosimilar approval, the U.S. Food and Drug Administration finalized its initial guidances describing the scientific and regulatory expectations for…

  10. PTABWatch

    Hatch-Waxman and BPCIA Patents May Be Exempted from Post-Grant Proceedings Under Pending Senate Legislation

    By John R. Labbé

    On Thursday, June 4, the Senate Judiciary Committee approved the Protecting American Talent and Entrepreneurship (PATENT) Act. We previously reported the significant provisions of the bill. Several members of the…